|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:activeIngredient
|
mRNA encoding SARS-CoV-2 spike protein
|
|
gptkbp:age
|
adults and children 6 months and older
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2020
|
|
gptkbp:ATCCode
|
gptkb:J07BX03
|
|
gptkbp:boosterDosing
|
single booster dose
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:brand
|
gptkb:Spikevax
|
|
gptkbp:contains
|
gptkb:plastic
acetic acid
sucrose
lipid nanoparticles
water for injection
sodium acetate
tromethamine
|
|
gptkbp:contraindication
|
severe allergic reaction to any component
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Moderna
|
|
gptkbp:dosingSchedule
|
two doses, 28 days apart
|
|
gptkbp:emergencyServices
|
granted in multiple countries
|
|
gptkbp:form
|
suspension for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Spikevax
|
|
gptkbp:indication
|
prevention of COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Moderna,_Inc.
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_Kingdom
gptkb:United_States
many other countries
|
|
gptkbp:otherName
|
gptkb:Moderna_COVID-19_Vaccine
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
muscle pain
chills
pain at injection site
|
|
gptkbp:storage
|
-25°C to -15°C
|
|
gptkbp:variantTargeted
|
gptkb:Omicron_(in_updated_formulations)
gptkb:original_SARS-CoV-2
|
|
gptkbp:WHOEmergencyUseListing
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Moderna
|
|
gptkbp:bfsLayer
|
4
|